BIO Announces 2002-2003 Board of Directors

Toronto (June 12, 2002) - The Biotechnology Industry Organization (BIO) has named its 2002-2003 Board of Directors, which includes nine new members: Goran Ando, M.D., executive vice president/president for research and development of Pharmacia Corporation; Andrew Baum, president and CEO of SemBioSys Genetics, Inc.; Joshua Boger, Ph.D., chairman and CEO of Vertex Pharmaceuticals, Inc.; Bruce L.A. Carter, Ph.D., president and CEO of ZymoGenetics, Inc.; Russell Howard, Ph.D., CEO of Maxygen; Richard DiMarchi, Ph.D., group vice president of Eli Lilly and Company; W. Scott Harkonen, M.D., president and CEO of InterMune, Inc.; Mitchel Sayare, chairman and CEO of ImmunoGen Inc.; and Leonard Schleifer, M.D., Ph.D., president and CEO of Regeneron Pharmaceuticals, Inc. David E. Robinson will continue as chairman of the board. Robinson is chairman, president and CEO of Ligand Pharmaceuticals, Inc.

"Our board includes leaders of companies at every stage of development, from startups to large-cap multinationals," said BIO President Carl B. Feldbaum. "That breadth of experience among BIO's stewards will serve our membership well over the coming year as we deal with multiple challenges: Medicare reform and efforts to design a prescription drug benefit, implementation of the Prescription Drug User Fee Act, acceptance of agricultural biotechnology, acceleration of biodefense research, tax and accounting proposals, and a range of international trade and patent issues."

Board of Directors

* Goran Ando, M.D.
Executive Vice President/
President for R&D
Pharmacia Corporation
Peapack, NJ
Benjamin F. McGraw, Ph.D.
Chairman, President & CEO
Valentis, Inc.
Burlingame, CA
David W. Anstice
President, Human Health-
The Americas
Merck & Co., Inc.
North Wales, PA
Alex McPherson, M.D., Ph.D.
President & CEO
Biomira, Inc.
Edmonton, Alberta, Canada
*Andrew Baum
President & CEO
SemBioSys Genetics, Inc.
Calgary, Alberta, Canada
Howard L. Minigh
Group Vice President
DuPont Biosolutions Enterprise
Wilmington, DE
Ernesto Bertarelli
Chief Executive Officer
Serono International SA
Geneva, Switzerland
Walter H. Moos, Ph.D.
Chairman and CEO
San Diego, CA
Simon G. Best
Chief Executive Officer
Ardana Bioscience LTD
Edinburgh, United Kingdom
James C. Mullen
President & CEO
Biogen, Inc.
Cambridge, MA
* Joshua Boger, Ph.D.
Chairman & CEO
Vertex Pharmaceuticals, Inc.
Cambridge, MA
H. Stewart Parker
President & CEO
Targeted Genetics Corporation
Seattle, WA
* Bruce L.A. Carter, Ph.D.
President & CEO
ZymoGenetics, Inc.
Seattle, WA
Richard F. Pops
Chief Executive Officer
Alkermes, Inc.
Cambridge, MA
Nancy T. Chang, Ph.D.
President & CEO
Tanox, Inc.
Houston, TX
Edwin C. Quattlebaum, Ph.D.
Chairman, President & CEO
MetaMorphix, Inc.
Savage, MD
Robert Chess
Inhale Therapeutic Systems, Inc.
San Carlos, CA
Hollings C. Renton
Chairman and CEO
Onyx Pharmaceuticals, Inc.
Richmond, CA
* Richard D. DiMarchi, Ph.D.
Group Vice President
Eli Lilly and Company
Indianapolis, IN
Norbert G. Riedel, Ph.D.
Corporate Vice President
& Chief Scientific Officer
Baxter International, Inc.
Roundlake, IL
Douglas A. Doerfler
President and CEO
MaxCyte, Inc.
Rockville, MD
David E. Robinson
Chairman, President & CEO
Ligand Pharmaceuticals, Inc.
San Diego, CA
Dennis M. Fenton, Ph.D.
Executive Vice President
Thousand Oaks, CA
Duane J. Roth
Chairman & CEO
Alliance Pharmaceutical Corp.
San Diego, CA
A. Charles Fischer
President & CEO
Dow AgroSciences
Indianapolis, IN
Una S. Ryan, Ph.D.
President & CEO
AVANT Immunotherapeutics, Inc.
Needham, MA
Edward V. Fritzky
Chairman, CEO, and President
Immunex Corporation
Seattle, WA
* Mitchel Sayare, Ph.D.
Chairman & CEO
ImmunoGen, Inc.
Cambridge, MA
L. Patrick Gage, Ph.D.
Wyeth Research
Collegeville, PA
* Leonard S. Schleifer, M.D., Ph.D.
President & CEO
Regeneron Pharmaceuticals, Inc.
Tarrytown, NY
Donal Geaney
Chairman and CEO
Elan Corporation, plc
Dublin, Ireland
Stephen A. Sherwin, M.S.
Chairman & CEO
Cell Genesys, Inc.
Foster City, CA
* W. Scott Harkonen, M.D.
President and CEO
InterMune, Inc.
Brisbane, CA
Edward T. Shonsey
President & CEO
Syngenta Seeds, Inc.
Golden Valley, MN
William A. Haseltine, Ph.D.
Chairman and CEO
Human Genome Sciences, Inc.
Rockville, MD
Mark Skaletsky
Chairman & CEO
Essential Therapeutics
Waltham, MA
Susan Desmond Hellmann, M.D., M.P.H.
Executive Vice President, Development
& Product Operations and
Chief Medical Officer
Genentech, Inc.
South San Francisco, CA
Frederick W. Telling, Ph.D.
Vice President, Corporate Policy
& Strategic Management
Pfizer, Inc.
New York, NY
Wayne T. Hockmeyer, Ph.D.
MedImmune, Inc.
Gaithersburg, MD
Henri A. Termeer
Chairman and CEO
Genzyme Corporation
Cambridge, MA
* Russell J. Howard, Ph.D.
Chief Executive Officer
Maxygen, Inc.
Redwood City, CA
Hendrik Verfaillie
President & CEO
Monsanto Company
St. Louis, MO
Vaughn M. Kailian
Vice Chairman
Millennium Pharmaceuticals, Inc.
Cambridge, MA
Roy A. Whitfield
Chairman of the Board of Directors
Incyte Genomics, Inc.
Palo Alto, CA
Louis G. Lange, M.D., Ph.D.
Chairman and CEO
CV Therapeutics, Inc.
Palo Alto, CA
Thomas G. Wiggans
President & CEO
Connetics Corporation
Palo Alto, CA
Edward Lanphier
President & CEO
Sangamo BioSciences, Inc.
Richmond, CA

* New Board Member